These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25971270)

  • 21. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
    Harousseau JL; Attal M; Leleu X; Troncy J; Pegourie B; Stoppa AM; Hulin C; Benboubker L; Fuzibet JG; Renaud M; Moreau P; Avet-Loiseau H
    Haematologica; 2006 Nov; 91(11):1498-505. PubMed ID: 17043025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
    Tsurumi H
    Rinsho Ketsueki; 2014 Oct; 55(10):2027-35. PubMed ID: 25297768
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
    J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 27. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Bianchi G; Richardson PG; Anderson KC
    J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
    J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
    Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
    Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Telek B; Méhes L; Batár P; Kiss A; Udvardy M
    Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
    Tovar N; Cibeira MT; Rosiñol L; Solé M; de Larrea CF; Escoda L; Rovira M; Bladé J
    Eur J Haematol; 2012 Oct; 89(4):340-4. PubMed ID: 22690902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.